DSM Pharmaceutical Products has signed a commercial agreement with a major pharma company for contract manufacturing services using its proprietary XD high cell density process technology. Karen King, president of DSM Biologics, commented, “We are proud to announce that a major pharma company has chosen DSM’s services and technology for three of their leading antibody pipeline projects for different indications. We will apply our XD technology in combination with our technology port...